Tech Company Financing Transactions
Akebia Therapeutics Funding Round
MDA Venture Philanthropy and private investors participated in a $1.5 million funding round for Akebia Therapeutics. This venture round was recorded on 7/3/2014.
Transaction Overview
Company Name
Announced On
7/3/2014
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the capital to fund clinical development of HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 First St. 1100
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Akebia Therapeutics is a biopharmaceutical company and global leader in developing therapies using hypoxia inducible factor (HIF) to treat serious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Butler
Chief Financial Officer
Jason Amello
VP - Bus. Development
Karen Tubridy
VP - General Counsel
Nikki Hadas
VP - Human Resources
Tamara Dillon
VP - Operations
Michel Dahan
Browse more venture capital transactions:
Prev: 7/3/2014: Inkling venture capital transaction
Next: 7/3/2014: Second Sight Medical Products venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs